Key facts
- This page summarizes Roger Sawhney's Form 4 filing for Arbutus Biopharma Corp (ABUS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jun 2026, 16:05.
Roger Sawhney - 08 Jun 2026 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)
- Reporting relationship
- Director
- Issuer ticker
- ABUS
- Reported as of
- 08 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2026, 16:05:32 UTC
- Prior SEC filing
- 22 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tuan Nguyen as attorney-in-fact for Roger Sawhney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Roger Sawhney filed Form 4 for Arbutus Biopharma Corp (ABUS) on 10 Jun 2026.
Change
- Previous filing in this sequence was filed on 22 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001858748
Primary reporting owner
Sawhney Roger
- Relationship
- Director
- Address
- C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER
- Signature
- /s/ Tuan Nguyen as attorney-in-fact for Roger Sawhney
- Signature date
- 10 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABUS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +78,800
- Change %
- Price
- $0.000000*
- Shares after
- 78,800
- Date
- 08 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 78,800
- Exercise price
- $4.24
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
Footnote F2
The option is fully vested and exercisable as of the date of the grant.